 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: NANOBIOTIX Euronext: NANO NASDAQ: NBTX the Company, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2021. First Half Operational Highlights, Pipeline Status and Upcoming Milestones Priority Pathway in Head 